Varicella-zoster virus (VZV) is one of the 8 herpetic viruses known to cause human infection and is found worldwide. Primary infection with varicella causes chickenpox. Following primary infection, the virus remains latent in neural ganglia, and upon subsequent reactivation VZV may cause herpes zoster (shingles), a disease mainly affecting older adults and immunocompromised persons.Reference Hope-Simpson 1 – Reference Harpaz, Ortega-Sanchez and Seward 2
Current US adult vaccination schedules allow adults to be considered immune to varicella if they meet any of the following criteria: documentation of 2 doses of varicella vaccine at least 4 weeks apart; US-born before 1980 (except healthcare personnel [HCP] and pregnant women); history of varicella-zoster based on diagnosis or verification of varicella-zoster by a healthcare provider; or laboratory evidence of immunity or laboratory confirmation of disease. 3 In 2011, the Centers for Disease Control and Prevention (CDC) changed their recommendation for varicella immunity for HCP, no longer allowing self-reported history of disease or US-born before 1980 as proof of immunity. 4
Owing to the 2011 change in CDC recommendations, our institution has been updating HCP immunization records to include laboratory evidence of disease for personnel with a self-reported history of disease. Our cohort was divided into born before, in, or after 1980. On the basis of epidemiologic data, the CDC recommends that US individuals born before 1980 may be considered immune to varicella, with the exception of HCP. This research brief reports our experience with catch-up varicella-zoster titers in our HCP.
The University of North Carolina Health Care System comprises 9 hospitals. The main facility, where most university HCP work or practice, is UNC Hospitals, an 853-bed tertiary care academic teaching hospital. All HCP participate in an immunization program that follows the CDC recommendations for proof of immunity. For the calendar year January to December 2014, new and incumbent HCP were screened because they could not provide written evidence of immunity to varicella. Of note, this cohort did not include HCP who reported varicella vaccination but did not have records; this group was revaccinated. Country of origin was not available.
Varicella-zoster immune status was assayed using a qualitative, chemiluminescence immunoassay for the detection of immunoglobulin G antibodies to VZV in human serum (DiaSorin). The cost of each test at our institution (excluding clinical staff and HCP time) was US $81. A 2-sided Fisher exact test was used with significance set at P≤.05.
A total of 413 varicella-zoster titers were drawn in 2014 (Table 1). Overall, 96% of HCP with a history of VZV infection had positive titers (97% of HCP born before 1980, 95% of HCP born in or after 1980). There was no statistical difference in the rate of varicella-zoster test positivity between those born before and after 1980 (P=.288, 2-sided Fisher exact test). Fifteen HCP tested other than positive (13 negative titers, 2 equivocal titers). For HCP who did not test positive, 8 were born in or after 1980 and 7 were born before 1980 (including equivocal titers).
Serologic Testing for Immunity to Varicella-Zoster Virus (VZV) for Healthcare Personnel (HCP) January–December 2014

NOTE. Varicella-zoster immune status was assayed with a qualitative, chemiluminescence immunoassay for the detection of immunoglobulin G antibodies to VZV in human serum (Liaison VZV IgG). Diagnostic specificity: 97.1% (68/70) (95% CI, 90.1%–99.7%) and diagnostic sensitivity: 100.0% (319/319) (95% CI, 98.9%–100.0%) are Reference to WHO Standard: Calibrated against WHO International Preparation W1044.
a Age cut-off used for determining presumed VZV immunity for all persons other than healthcare providers. 3
b There was no statistical difference in the rate of varicella-zoster test positivity between those born before and after 1980 (P =.283, 2-sided Fisher exact test).
c N x $81/test.
d Total costs/no. of negative tests.
Several articles have assessed VZV immunity in hospital-based populations of HCP, but there are no recent reports on VZV immunity in US HCP. Seroprevalence to VZV in HCP has been reported to be between 71% and 99%, although in some cases, testing was performed on HCP with a history of varicella vaccination. Reference dos Santos, Ono and Lobato 5 – Reference Talebi-Taher, Noori, Shamshiri and Barati 7 There are also known differences in adult seroprevalence rates by country, making it important to have country-specific data.Reference Talebi-Taher, Noori, Shamshiri and Barati 7 – Reference Chodick, Ashkenazi, Livni and Lerman 9
Our data demonstrated that 96% of new and incumbent HCP at our institution had VZV immunity (ie, positive titer). The overall cost to find an HCP without VZV immunity was more than $2,000; this cost dropped to $1,500 if testing was limited to HCP born in or after 1980. However, even though the data suggested that it may be unnecessary to draw VZV titers in US HCP, there are other administrative reasons that may require titer-proven immunity. This includes HCP who are credentialed at multiple healthcare facilities with differing immunization requirements and students who may be required to have proof of immunization beyond a self-reported history of vaccination or disease. 10
In conclusion, VZV titers in a sample of US HCP in 2014 show a seroprevalence of immunity to VZV greater than 96%. Cost analysis suggests that limiting testing to those born in or after 1980 would identify many of the susceptible HCP at a substantial cost savings. Increasing VZV documentation requirements in elementary, secondary, and university students will likely reduce the future need for occupational health programs to perform widespread testing for VZV immunity.
ACKNOWLEDGMENTS
Financial support. None reported.
Potential conflicts of interest. D.J.W. reports that he is a consultant for MSD. All other authors report no conflicts of interest relevant to this article.

